Impairment of the NKT–STAT1–CXCL9 axis contributes to vessel fibrosis in pulmonary hypertension caused by lung fibrosis
K Jandl, LM Marsh, AC Mutgan, S Crnkovic… - American Journal of …, 2022 - atsjournals.org
Rationale: Pulmonary hypertension (PH) is a common, severe comorbidity in interstitial lung
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …
Impairment of the NKT-STAT1-CXCL9-axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Due to Lung Fibrosis.
K Jandl, LM Marsh, AC Mutgan, S Crnkovic… - American Journal of …, 2022 - europepmc.org
Objective To identify a novel functional link between natural killer T (NKT) cell activation and
vascular fibrosis in PF-PH. Methods Multicolor flow cytometry, secretome and immuno …
vascular fibrosis in PF-PH. Methods Multicolor flow cytometry, secretome and immuno …
Impairment of the NKT-STAT1-CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis
K Jandl, LM Marsh, AC Mutgan… - … of respiratory and …, 2022 - pubmed.ncbi.nlm.nih.gov
Rationale: Pulmonary hypertension (PH) is a common, severe comorbidity in interstitial lung
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …
Impairment of the NKT-STAT1-CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis.
K Jandl, LM Marsh, AC Mutgan… - American Journal of …, 2022 - search.ebscohost.com
Rationale: Pulmonary hypertension (PH) is a common, severe comorbidity in interstitial lung
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …
diseases such as pulmonary fibrosis (PF), and it has limited treatment options. Excessive …